Clinical Trial Update: Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial results update for Ecteinascidin-743 (trabectedin) in patients with advanced soft tissue sarcoma; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Ecteinascidin 743 (trabectedin)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Brain and Central Nervous System Tumors, Endometrial Cancer | Phase 2 | Status: COMPLETED